Vanderbilt University Medical Center, under the direction of Dan Roden, M.D., is involved in clinical research to identify genetic markers associated with the development of drug-induced Torsades de Pointes (TdP) and Long QT (LQT).

Because of the relatively low incidence of drug-induced LQT/TdP, we are asking that colleagues with suspected cases refer history and ECG data for review as to patient eligibility. The study has been approved for remote consent by the Vanderbilt IRB.

The goal of the study is to search for new genes underlying risk for drug-induced torsades de pointes. All data from genomic analyses will be posted on public websites with no patient identifier.

Participating physicians are encouraged to report cases of drug-induced LQT/TdP to Dan Roden, M.D. Dan.Roden@Vanderbilt.edu or Kris Norris RN Kris.norris@vanderbilt.edu.

One of the following must be present:

1. An uncorrected QT interval >=600 msec while on drug that decreased to <480 msec following withdrawal of drug OR
2. An episode of TdP documented by ECG with an ECG without evidence of TdP following withdrawal of drug OR
3. TdP in addition to LQT (for subjects with bundle branch block or a pacemaker) at the time of the event.

1. Potassium level <= 3mmol at onset of event (1mEq/L=1mmol).
2. Subarrachnoid hemorrhage at onset of event.
3. Cardiac bypass <24 hours before onset of event.
4. Hospital admission diagnosis of hypothermia @ time of event.
5. Diagnosed with congenital LQT syndrome prior to onset of event.
6. Leukopenic (WBC <1000 cells/ml) at onset of event
7. History of a non-autologous bone marrow transplant at anytime in the past.

To receive a kit for enrollment and further information about the study you may contact: